Longing for clinical excellence: A critical outlook into the NICE recommendations on hypertension management-is nice always good?

Journal of Hypertension

Volumn 30, Issue 4, 2012, Pages 660-668

  Zanchetti, Alberto ^a   Mancia, Giuseppe ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

antihypertensive treatment; hypertension guidelines; mbulatory blood pressure monitoring; NICE guidelines; thiazide diuretics

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; INDAPAMIDE; THIAZIDE DIURETIC AGENT; VALSARTAN;

BLOOD PRESSURE MONITORING; HUMAN; HYPERTENSION; LOW DRUG DOSE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WHITE COAT HYPERTENSION;

EID: 84858699564     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328351b4e4     Document Type: Review

References (72)

1. World Health Organization. Arterial hypertension. Report of a WHO Expert Committee. Geneva: World Health Organization; 1978.
2. World Health Organization/International Society of Hypertension. Guidelines for the treatment of mild hypertension. Bull WHO 1983; 61:53-56.
3. Guidelines Sub-Committee. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1989; 7:689-693.
4. World Health Organization Guidelines Committee. Prevention of hypertension and associated cardiovascular disease: a 1991 statement. Clin Exp Hypertens 1992; 14:333-341.
5. Guidelines Sub-Committee. Guidelines for the management of mild hypertension memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11:905-918.
6. World Health Organization. Hypertension Control. Report of a WHO Expert Committee. Geneva: World Health Organization; 1996.
7. Guidelines Sub-Committee. World Health Organization/International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17:151-183.
8. Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
10. Arnow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 2011; 57:2037-2114.
11. National Institute for Health and Clinical Excellence (NICE). Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127. 2011. www.nice.org.uk/guidance/CG127 [accessed August 2011].
12. Agency for Healthcare Policy and Research Publications. Acute pain management: operative and medical procedures and trauma. Rockville, MD: Agency for Healthcare Policy and Research Publications; 1992.
13. Zanchetti A. Evidence and wisdom: recommendations for forthcoming guidelines. J Hypertens 2011; 29:1-3.
14. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282:539-546. (Pubitemid 29380290)
15. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46:156-161. (Pubitemid 40946507)
16. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study. Circulation 2005; 111:1777-1783. (Pubitemid 40525142)
17. Mancia G, Sega R, Grassi G, Cesana G, Zanchetti A. Defining ambulatory and home blood pressure normality: further considerations based on data from the PAMELA study. J Hypertens 2001; 19:995-999. (Pubitemid 32493630)
18. Fagard R, Staessen J, Thijs L, Amery A. Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoring: a meta analysis of comparative studies. Am J Hypertens 1995; 8:533-540.
19. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, et al. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:2422-2427. (Pubitemid 35278796)
20. Staessen JA, Fagard RH, Lijnen PJ, Thijs L, Van Hood R, Amery AK. Mean and range of the ambulatory pressure in normotensive subjects from a meta-analysis of 23 studies. Am J Cardiol 1991; 67:723-727.
21. Mancia G, Sega R, Bravi C, De Vito G, Valagussa F, Cesana G, Zanchetti A. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995; 13:1377-1390. (Pubitemid 26015753)
22. Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, et al. International Database on Ambulatory Blood Pressure In Relation to Cardiovascular Outcomes Investigators. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 2010; 28:2036-2045.
23. Li Y, Boggia J, Thijs L, Hansen TW, Kikuya M, Björklund- Bodega°rd K, Richart T, et al. International Database on Ambulatory Blood Pressure Monitoring in relation to Cardiovascular Outcomes Investigators. Is blood pressure during the night more predictive of cardiovascular outcome than during the day? Blood Press Monit 2008; 13:145-147.
24. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347:797-805. (Pubitemid 34988338)
25. Parati G, Pomidossi G, Casadei R, Malaspina D, Colombo A, Ravogli A, Mancia G. Ambulatory blood pressure monitoring does not interfere with the haemodynamic effects of sleep. J Hypertens 1985; 3:S107-109.
26. Di Rienzo M, Grassi G, Pedotti A, Mancia G. Continuous vs intermittent blood pressure measurements in estimating 24-h average blood pressure. Hypertension 1983; 5:264-269. (Pubitemid 13164355)
27. Di Rienzo M, Parati G, Pomidossi G, Veniani M, Pedotti A, Mancia G. Blood pressure monitoring over short day and night times cannot predict 24-h average blood pressure. J Hypertens 1985; 3:343-349. (Pubitemid 15017652)
28. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2001; 104:1385-1392. (Pubitemid 32880151)
29. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension 2006; 47:846-853. (Pubitemid 44297554)
30. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, et al. Short-and long-term incidence of stroke in white coat hypertension. Hypertension 2005; 45:203-208. (Pubitemid 40179961)
31. Weber MA, Neutel JM, Smith DH, Graettinger WF. Diagnosis of mild hypertension by ambulatory blood pressure monitoring. Circulation 1994; 90:2291-2298. (Pubitemid 24354314)
32. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Grassi G, Sega R. Increased long-term risk of new-onset diabetes mellitus in white coat and masked hypertension. J Hypertens 2009; 27:1672-1678.
33. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Friz H-P, et al. Long-term risk of sustained hypertension in white coat or masked hypertension. Hypertension 2009; 54:226-232.
34. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, et al. Prognosis of masked hypertension and white-coat hypertension detected by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 2005; 46:508-515.
35. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular prognosis of 'masked hypertension' detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291:1342-1349. (Pubitemid 38541649)
36. Bjorklund K, Lind L, Zethelius B, Andren B, Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation 2003; 107:1297-1302. (Pubitemid 36314414)
37. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 2007; 25:2193-2198. (Pubitemid 47537908)
38. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
39. Evans JG, Rose G. Hypertension. Br Med Bull 1971; 27:37-42.
40. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27:923-934.
41. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
42. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al., 'Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121-1123. (Pubitemid 351731743)
43. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002; 20:771-777. (Pubitemid 34913723)
44. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353:2008-2013. (Pubitemid 29271745)
45. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914-921. (Pubitemid 23086643)
46. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
47. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906. (Pubitemid 41265663)
48. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031. (Pubitemid 38781102)
49. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24:2163-2168. (Pubitemid 44611024)
50. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
51. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886. (Pubitemid 36677151)
52. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
53. Zanchetti A. Meta-analyses: first-rank evidence or second-hand information? Nat Rev Cardiol 2011; 8:249-251.
54. Zanchetti A, Crepaldi G, Bond MG, Gallus G, Veglia F, Mancia G, et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS: a randomized double-blind trial. Stroke 2004; 35:2807-2812. (Pubitemid 39565175)
55. Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den HE, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Arch Int Med 2001; 161:965-971. (Pubitemid 32295650)
56. Tresukosol D, Sriyudhasak O. Amlodipine and hydrochlorothiazide for isolated systolic hypertension in the Thai elderly. Siriraj Med J 2005; 57:374-379.
57. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized longterm placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23:2157-2172. (Pubitemid 41666745)
58. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2002; 342:145-153.
59. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al., ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559. (Pubitemid 351522739)
60. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
61. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1:1349-1354. (Pubitemid 15060905)
62. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304:405-412.
63. NICS Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension 1999; 34:1129-1133.
64. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372. (Pubitemid 30487492)
65. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
66. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA 2003; 289:2073-2082. (Pubitemid 37430209)
67. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616. (Pubitemid 29087980)
68. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365. (Pubitemid 30487491)
69. Zanchetti A. Evidence-based medicine in hypertension: what type of evidence? J Hypertens 2005; 23:1113-1120. (Pubitemid 40862711)
70. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
71. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). JAMA 1996; 276:785-791. (Pubitemid 26301577)
72. Mancia G, Zanchetti A. Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage. J Hypertens 2008; 26:164-168.